# AbbVie **Source:** https://geo.sig.ai/brands/abbvie **Vertical:** Healthcare **Subcategory:** General **Tier:** Leader **Website:** abbvie.com **Last Updated:** 2026-04-14 ## Summary Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition. ## Company Overview AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average. The company has successfully navigated the Humira patent cliff that began in 2023, when biosimilar competitors entered the US market after years of exclusivity. AbbVie's strategy to offset Humira erosion centered on Skyrizi (risankizumab, for psoriasis and Crohn's disease) and Rinvoq (upadacitinib, for rheumatoid arthritis and other immune conditions), both of which have grown rapidly to partially offset Humira's revenue decline. Revenue in 2024 was approximately $55 billion. In 2025, AbbVie completed its $8.7 billion acquisition of Cerevel Therapeutics to bolster its neuroscience pipeline with treatments for schizophrenia and Parkinson's disease. The company also acquired Aliada Therapeutics (Alzheimer's focused) for $1.4 billion. AbbVie's aesthetics franchise (Botox via Allergan acquisition, Juvederm) remains a significant revenue contributor. The company's 2025-2026 strategic priorities include advancing its neuroscience and oncology pipeline, executing the Allergan integration fully, and managing pricing pressures from the Inflation Reduction Act's drug negotiation provisions. ## Frequently Asked Questions ### What is AbbVie? AbbVie is a specialty biopharmaceutical company spun off from Abbott in 2013, focused on developing innovative treatments for complex diseases in rheumatology, dermatology, gastroenterology, oncology, neuroscience, and aesthetics. Ranked 77th on the Fortune 500 with $56.3 billion in 2024 revenues. ### What is Humira and why is it significant for AbbVie? Humira (adalimumab) is AbbVie's blockbuster biologic drug treating autoimmune diseases including rheumatoid arthritis, Crohn's disease, and psoriasis. It was the world's best-selling drug for many years, generating peak annual revenues exceeding $20 billion before biosimilar competition began in 2023. ### What drugs has AbbVie developed to replace Humira revenue? AbbVie's growth portfolio includes Skyrizi (risankizumab) for psoriasis and IBD, and Rinvoq (upadacitinib) for multiple inflammatory diseases. These two drugs are expected to collectively surpass Humira's peak revenues by the mid-2020s. ### What did AbbVie acquire Allergan? AbbVie acquired Allergan in 2020 for approximately $63 billion. The acquisition added Botox (both therapeutic and cosmetic), Juvederm dermal fillers, and other aesthetics products, diversifying AbbVie's revenue base beyond immunology. ### What therapeutic areas does AbbVie focus on? AbbVie focuses on immunology, oncology, neuroscience, and aesthetics. Its immunology portfolio is led by Humira, Skyrizi, and Rinvoq; oncology by Imbruvica and Venclexta; neuroscience by Vraylar and Ubrelvy; and aesthetics by Botox and Juvederm. ### How does AbbVie approach R&D investment? AbbVie invests heavily in R&D, spending approximately $7-8 billion annually. The company uses a combination of internal discovery and external acquisitions and licensing deals to build its pipeline across priority therapeutic areas. ### What is AbbVie's approach to biosimilar competition for Humira? AbbVie secured a multi-year IP settlement with biosimilar manufacturers that delayed U.S. competition until 2023 while biosimilars launched in Europe earlier. AbbVie executed a price adjustment strategy and focused on patient retention while pivoting growth to Skyrizi and Rinvoq. ### Is AbbVie a separate company from Abbott Laboratories? Yes, AbbVie was spun off from Abbott Laboratories in 2013 as an independent pharmaceutical company. While it shares its heritage with Abbott, AbbVie operates independently with its own stock listing, management, and pipeline focused on biopharmaceuticals. ## Tags analytics, b2b, enterprise, global, healthtech, public --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*